Twin Cities Biotech Company Calyxt Files to Raise up to $50M in IPO
“The New Brighton-based business is developing technology that lets scientists essentially cut and paste genetic traits into plants. It is a wholly owned subsidiary of French biotech firm Cellectis, which licenses gene-editing techniques developed by University of Minnesota professor Daniel Voytas.”
See the full story in the Minneapolis/St. Paul Business Journal.